Interleukin-3 gene therapy for cancer

Abstract

A method for treating of tumors, in particular malignant solid tumors, using adenovirus-derived material and IL-3, so that the adenovirus preferably encodes IL-3 activity, which is given systematically to a mammal, optionally in an isolated perfusion setting. Preferably, IL-3 activity is combined with other cytotoxic activity.

What is claimed is:  
     
         1 . A localized perfusion system for treating sarcoma and osteosarcoma tumors comprising a pharmaceutical composition having IL-3 activity and a pharmaceutical composition having cytostatic activity.  
     
     
         2 . The localized perfusion system of  claim 1 , wherein the IL-3 activity is provided by a recombinant adenoviral vector encoding said activity.  
     
     
         3 . The localized perfusion system of  claim 1 , wherein the pharmaceutical composition having cytostatic activity is in a single dosage unit for injection into a solid tumor.  
     
     
         4 . The localized perfusion system of  claim 1 , wherein the pharmaceutical composition comprising IL-3 activity is a perfusion fluid.  
     
     
         5 . The localized perfusion system of  claim 1 , wherein the perfusion fluid comprises a recombinant adenoviral vector in the form of a virus-like particle.  
     
     
         6 . The localized perfusion system of  claim 5 , wherein the virus-like particle is present in an amount of from about 1×10 6  to 5×10 9  iu.  
     
     
         7 . The localized perfusion system of  claim 5 , wherein both activities are present in a single combination.  
     
     
         8 . The localized perfusion system of  claim 1 , wherein the cytostatic activity is at least one of TNF-activity, Melphalan and adriamycin.  
     
     
         9 . A pharmaceutical composition for localized treatment of sarcoma and osteosarcoma tumors, said pharmaceutical composition consisting of: 
 a recombinant adenoviral vector comprising genetic information encoding IL-3 activity; and    a diluent.    
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the recombinant adenoviral vector is in the form of virus-like particles  
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the virus-like particles are present in said pharmaceutical composition an amount of about 1×10 6  to 5×10 9  in.  
     
     
         12 . The pharmaceutical composition of  claim 9 , wherein a virus-like particle is a human homolog of a recombinant adenovirus IG.Ad.CMV.rIL-3 deposited at the ECACC under accession number V96071634.  
     
     
         13 . A kit of parts for the reduction of growth of sarcoma and osteosarcoma tumors, said kit of parts comprising a pharmaceutical composition having IL-3 activity and cytostatic activity; 
 means for isolating certain tissues; and    means for perfunding said isolated tissues.    
     
     
         14 . The kit of parts of  claim 13 , wherein said cytostatic activity is TNF-activity.  
     
     
         15 . The kit of parts of  claim 13 , wherein the pharmaceutical composition having cytostatic activity is a single dosage unit for injection into a solid tumor.  
     
     
         16 . The kit of parts of  claim 13 , wherein the pharmaceutical composition comprises at least one of Melphalan and adriamycin.